Medonline
Dr. Rosalia Rutter
Dr. Rosalia Rutter
3. Juni 2019

ASCO 2019: Breakfast Brief – Head and neck cancer

PD DDr. Sacha Rothschild, University Hospital Basel, comments on this year’s head and neck cancer studies, as well as lung cancer trials.

Inhalte im Video:
00:00
KEYNOTE-048: Results support pembrolizumab and pembrolizumab + platinum + 5-FU for defined patients with recurrent metastatic HNSCC.
04:34
No benefit for the TPEx regime compared to standard therapy.
05:03
Ado-trastuzumab emtansine is highly efficacious in patients with HER2 amplified salivary gland cancers.
06:24
JIPANG: Pemetrexed/cisplatin shows similar efficacy compared to vinorelbine/cisplatin with better tolerability than adjuvant chemotherapy for completely resected stage II-IIIA non-squamous non-small-cell lung cancer.
07:38
LCMC3: Neoadjuvant atezolizumab in resectable NSCLC was well tolerated, and pCR and major pathologic response rates are encouraging
08:48
NEOSTAR: The study investigates neoadjuvant nivolumab or nivolumab plus ipilimumab on major pathologic response rates in resectable non-small-cell lung cancer
10:51
Lurbinectidin monotherapy shows promise as a second line treatment in SCLC.
Interview mit:
PD Dr. Sacha Rothschild
Interview von:
Dr. Rosalia Rutter
Produziert von:
Mag. Oliver Eberhardt